Showing 1 - 5 results of 5 for search 'Mark Holodniy', query time: 0.01s Refine Results
  1. 1
    Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment

    Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment by Paul Ravi Waldron, Mark Holodniy

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)—Database of a prospective longitudinal observational study within the Veterans Health Administration

    Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)—Database of a prospective longitudinal observational study within the Veterans Health Administration by Liuye Huang, Liuye Huang, Xumin Li, Xumin Li, Samin I. Kamal, Samin I. Kamal, Jonathan D. Sugimoto, Jonathan D. Sugimoto, Cindy H. Liu, Tracy Wang, Daniel K. Morelli, Jordanna B. Midthun, Vivek R. Pakanati, Katrina V. Deardorff, Jennifer L. Sporleder, Jude Lopez, Mark Holodniy, Mark Holodniy, Mark Holodniy, Nicholas L. Smith, Nicholas L. Smith, Jennifer S. Lee, Jennifer S. Lee, Javeed A. Shah, Javeed A. Shah, Javeed A. Shah, Jennifer M. Ross, Jennifer M. Ross

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.

    Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. by Lauren E Kushner, Aaron M Wendelboe, Laura C Lazzeroni, Aarthi Chary, Mark A Winters, Anu Osinusi, Shyam Kottilil, Michael A Polis, Mark Holodniy

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review.

    Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. by Clay Bavinger, Eran Bendavid, Katherine Niehaus, Richard A Olshen, Ingram Olkin, Vandana Sundaram, Nicole Wein, Mark Holodniy, Nanjiang Hou, Douglas K Owens, Manisha Desai

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

    Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. by Mark Holodniy, Sheldon T Brown, D William Cameron, Tassos C Kyriakides, Brian Angus, Abdel Babiker, Joel Singer, Douglas K Owens, Aslam Anis, Ruth Goodall, Fleur Hudson, Mirek Piaseczny, John Russo, Martin Schechter, Lawrence Deyton, Janet Darbyshire, OPTIMA Team

    Published 2011-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: